Accès libre

Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab

À propos de cet article

Citez

Robert Königsberg
Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna) – LB Cluster Translational Oncology, 3rd Medical Department – Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria / Applied Cancer Research – Institution for Translational Research Vienna (ACR –ITR VIEnna), Vienna, Austria
Julia Maierhofer
Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna) - LB Cluster Translational Oncology, 3rd Medical Department - Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria
Tanja Steininger
Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna) - LB Cluster Translational Oncology, 3rd Medical Department - Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria/ Applied Cancer Research – Institution for Translational Research Vienna (ACR –ITR VIEnna), Vienna, Austria
Gabriele Kienzer
Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna) - LB Cluster Translational Oncology, 3rd Medical Department - Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria / Institute for Radiodiagnostics, Kaiser Franz Josef-Spital, Vienna, Austria
Christian Dittrich
Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna) - LB Cluster Translational Oncology, 3rd Medical Department - Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria / Applied Cancer Research – Institution for Translational Research Vienna (ACR –ITR VIEnna), Vienna, Austria
eISSN:
1581-3207
ISSN:
1318-2099
Langue:
Anglais
Périodicité:
4 fois par an
Sujets de la revue:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology